Colchicine biotransformation by human liver microsomes - Identification of CYP3A4 as the major isoform responsible for colchicine demethylation

被引:104
作者
Tateishi, T
Soucek, P
Caraco, Y
Guengerich, FP
Wood, AJJ
机构
[1] VANDERBILT UNIV, SCH MED, DIV CLIN PHARMACOL, DEPT BIOCHEM, NASHVILLE, TN 37232 USA
[2] VANDERBILT UNIV, SCH MED, CTR MOL TOXICOL, NASHVILLE, TN 37232 USA
关键词
colchicine; CYP3A4; cytochrome P450; drug metabolism; drug interaction;
D O I
10.1016/S0006-2952(96)00693-4
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Colchicine disposition involves both active biliary and renal excretion of parent drug, and at least in mammals a substantial fraction undergoes hepatic demethylation prior to excretion. We investigated the biotransformation of [H-3]colchicine in a panel of microsomal preparations obtained from sixteen human liver samples. The production rate of the main metabolites of colchicine's 3-demethylcolchicine (3DMC) and 2-demethylcolchicine (2DMC), was linear in relation to incubation time, cytochrome (P450) content, and substrate concentration. Following the incubation of colchicine (5 nM) with microsomes in the presence of an NADPH-generating system for 60 min, 9.8% and 5.5% of the substrate were metabolized to 3DMC and 2DMC, respectively. The formation rate of colchicine metabolites exhibited a marked variation between the different microsomal preparations. The formation rates of both colchicine metabolites were correlated significantly with nifedipine oxidase activity, a marker of CYP3A4 activity (r = 0.96, P < 0.001), but not with the metabolic markers of CYP2A6, CYP2C19, CYP2C9, CYP2D6, and CYP2E1 activities. Chemical inhibition of CYP3A4 by preincubation with gestodene (40 mu M) or troleandomycin (40 mu M) reduced the formation of 3DMC and 2DMC by 70 and 80%, respectively, whereas quinidine, diethyldithiocarbamate, and sulfaphenazole had no inhibitory effect. Similarly, antibodies raised against CYP3A4 almost completely abolished colchicine demethylation and nifedipine oxidase activity, but preimmune IgG had no effect. In conclusion, colchicine was metabolized to 3DMC and 2DMC by human liver microsomes. The production of colchicine metabolites was mediated by CYP3A4, and its rate varied greatly between microsomal preparations obtained from different liver samples. The coadministration of colchicine with known inhibitors or substrates of CYP3A4 may inhibit colchicine metabolism, resulting in concentration-related toxicity. Copyright (C) 1996 Elsevier Science Inc.
引用
收藏
页码:111 / 116
页数:6
相关论文
共 25 条
[1]  
ALARCONSEGOVIA D, 1979, J RHEUMATOL, V6, P705
[2]   BIOACTIVE ALKALOIDS .4. RESULTS OF RECENT INVESTIGATIONS WITH COLCHICINE AND PHYSOSTIGMINE [J].
BROSSI, A .
JOURNAL OF MEDICINAL CHEMISTRY, 1990, 33 (09) :2311-2319
[3]  
CARACO Y, 1992, J RHEUMATOL, V19, P494
[4]   HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHIC SEPARATION OF COLCHICINE AND ITS PHENOLIC AND N-DESACETYLATED DERIVATIVES [J].
DAVIS, PJ ;
KLEIN, AE .
JOURNAL OF CHROMATOGRAPHY, 1980, 188 (01) :280-284
[5]  
Eliakim M., 1981, RECURRENT POLYSEROSI
[6]   MECHANISM-BASED INACTIVATION OF HUMAN LIVER MICROSOMAL CYTOCHROME-P-450-IIIA4 BY GESTODENE [J].
GUENGERICH, FP .
CHEMICAL RESEARCH IN TOXICOLOGY, 1990, 3 (04) :363-371
[7]  
HUNTER AL, 1975, J PHARMACOL EXP THER, V192, P605
[8]   A PROSPECTIVE TRIAL OF COLCHICINE FOR PRIMARY BILIARY-CIRRHOSIS [J].
KAPLAN, MM ;
ALLING, DW ;
ZIMMERMAN, HJ ;
WOLFE, HJ ;
SEPERSKY, RA ;
HIRSCH, GS ;
ELTA, GH ;
GLICK, KA ;
EAGEN, KA .
NEW ENGLAND JOURNAL OF MEDICINE, 1986, 315 (23) :1448-1454
[9]  
KREHENNOBICH D, 1988, NEW ENGL J MED, V318, P1709
[10]  
LEVY M, 1991, PHARMACOTHERAPY, V11, P196